WO2003106624A3 - Cancer-linked gene as target for chemotherapy - Google Patents

Cancer-linked gene as target for chemotherapy Download PDF

Info

Publication number
WO2003106624A3
WO2003106624A3 PCT/US2003/018431 US0318431W WO03106624A3 WO 2003106624 A3 WO2003106624 A3 WO 2003106624A3 US 0318431 W US0318431 W US 0318431W WO 03106624 A3 WO03106624 A3 WO 03106624A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
target
disclosed
chemotherapy
linked gene
Prior art date
Application number
PCT/US2003/018431
Other languages
French (fr)
Other versions
WO2003106624A2 (en
Inventor
Krista Evans
Reinhard Ebner
Original Assignee
Avalon Pharmaceuticals
Krista Evans
Reinhard Ebner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals, Krista Evans, Reinhard Ebner filed Critical Avalon Pharmaceuticals
Priority to AU2003245448A priority Critical patent/AU2003245448A1/en
Publication of WO2003106624A2 publication Critical patent/WO2003106624A2/en
Publication of WO2003106624A3 publication Critical patent/WO2003106624A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cancer-linked gene sequences, and derived amino acid sequences, are disclosed along with processes for assaying potential antitumor agents based on their modulation of the expression of these cancer-linked genes. Also disclosed are antibodies that react with the disclosed polypeptides and methods of using the antibodies to treat cancerous conditions, such as by using the antibody to target cancerous cells in vivo for purposes of delivering therapeutic agents thereto. Also described are methods of diagnosing using the gene sequences.
PCT/US2003/018431 2002-06-13 2003-06-11 Cancer-linked gene as target for chemotherapy WO2003106624A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003245448A AU2003245448A1 (en) 2002-06-13 2003-06-11 Cancer-linked gene as target for chemotherapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38867202P 2002-06-13 2002-06-13
US60/388,672 2002-06-13
US39796602P 2002-07-23 2002-07-23
US60/397,966 2002-07-23

Publications (2)

Publication Number Publication Date
WO2003106624A2 WO2003106624A2 (en) 2003-12-24
WO2003106624A3 true WO2003106624A3 (en) 2004-12-09

Family

ID=29740051

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/018431 WO2003106624A2 (en) 2002-06-13 2003-06-11 Cancer-linked gene as target for chemotherapy

Country Status (2)

Country Link
AU (1) AU2003245448A1 (en)
WO (1) WO2003106624A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876996A (en) * 1997-07-25 1999-03-02 Incyte Pharmaceuticals, Inc. Human S-adenosyl-L-methionine methyltransferase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876996A (en) * 1997-07-25 1999-03-02 Incyte Pharmaceuticals, Inc. Human S-adenosyl-L-methionine methyltransferase

Also Published As

Publication number Publication date
AU2003245448A8 (en) 2003-12-31
WO2003106624A2 (en) 2003-12-24
AU2003245448A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
WO2003105758A3 (en) Cancer-linked gene as target for chemotherapy
WO2003104399A3 (en) Cancer-linked gene as target for chemotherapy
WO2003097803A3 (en) Cancer-linked gene as target for chemotherapy
WO2003101400A3 (en) Cancer-linked gene as target for chemotherapy
WO2008020596A3 (en) Treating or preventing cancers over-expressing reg4 or kiaa0101
WO2005077091A3 (en) Nicotinamide riboside kinase compositions and methods for using the same
WO2007113648A3 (en) Ctla4 antibody combination therapy
WO2003072125A8 (en) Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
EP1004022A4 (en) Methods and compositions for overcoming resistance to biologic and chemotherapy
CR20220317A (en) Anti-cd73 antibodies and uses thereof
MX2009013646A (en) Methods of diagnosing and treating cancer.
PL335334A1 (en) Combined treatment involing suppressor gene tumour therapy and chemotherapy for use in antineoplastic therapy
WO2005120588A3 (en) Peptides delivered to cell nuclei
WO2004078215A3 (en) Use of antibody conjugated deoxycytidine kinase for adept
MXPA05011085A (en) Compositions and methods relating to stop-1.
WO2003104401A3 (en) Cancer-linked gene as target for chemotherapy
WO2003104438A3 (en) Cancer-linked gene as target for chemotherapy
WO2003076579A3 (en) Cancer-linked gene as target for chemotherapy
WO2003097802A3 (en) Cancer-linked gene as target for chemotherapy
WO2002031198A3 (en) Cancer-linked genes as targets for chemotherapy
WO2003105783A3 (en) Cancer-linked gene as target for chemotherapy
WO2005079490A3 (en) Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
WO2004026238A8 (en) Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers
WO2003104419A3 (en) Cancer-linked gene as target for chemotherapy
WO2003104404A8 (en) Cancer-linked gene as target for chemotherapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP